Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Painreform Ltd (PRFX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PRFX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.84% | Avg. Invested days 7 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.84M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.62 | 52 Weeks Range 1.25 - 16.63 | Updated Date 06/30/2025 |
52 Weeks Range 1.25 - 16.63 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -32.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -126.89% | Return on Equity (TTM) -321.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1377472 | Price to Sales(TTM) - |
Enterprise Value -1377472 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.32 | Shares Outstanding 2013140 | Shares Floating 1340751 |
Shares Outstanding 2013140 | Shares Floating 1340751 | ||
Percent Insiders 9.62 | Percent Institutions 2.17 |
Analyst Ratings
Rating 1 | Target Price 12 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Painreform Ltd
Company Overview
History and Background
There is no publicly traded US stock named Painreform Ltd. Therefore, no real historical information is available. Assuming this is a hypothetical company, a general background cannot be created. The following data is placeholder.
Core Business Areas
- Segment Name 1: Pain Management Pharmaceuticals: Development, manufacturing, and sales of prescription pain medications.
- Segment Name 2: Over-the-Counter (OTC) Pain Relief: Production and distribution of non-prescription pain relief products.
- Segment Name 3: Pain Management Devices: Development and sales of medical devices for pain relief, such as TENS units.
Leadership and Structure
Hypothetical example: CEO John Doe, CFO Jane Smith. The organizational structure could be functional, with departments for R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- Product Name 1: OxyContin (Hypothetical Generic): A prescription opioid pain reliever. Market share is highly competitive with multiple generics. Competitors: Teva Pharmaceutical Industries (TEVA), Mylan (now Viatris, VTRS).
- Product Name 2: PainAway Cream: An OTC topical pain relief cream. Relatively small market share versus established brands. Competitors: Johnson & Johnson (JNJ), GlaxoSmithKline (GSK).
Market Dynamics
Industry Overview
The pain management industry is large and growing, driven by an aging population and increasing prevalence of chronic pain. It is highly regulated and faces pressure from opioid abuse concerns.
Positioning
Hypothetical: Painreform Ltd could be positioned as a diversified pain management company, focusing on both prescription and OTC products.
Total Addressable Market (TAM)
The global pain management market is estimated at $80 billion. Painreform's positioning relative to TAM depends on the success of their products in capturing market share.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio (pharmaceuticals, OTC, devices)
- Strong R&D capabilities (hypothetical)
- Established distribution network (hypothetical)
Weaknesses
- High reliance on opioid pain relievers
- Exposure to litigation risks
- Intense competition
Opportunities
- Development of non-opioid pain treatments
- Expansion into emerging markets
- Acquisition of smaller pain management companies
Threats
- Increased regulatory scrutiny
- Generic competition
- Public perception of opioid abuse
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- ABBV
- VTRS
Competitive Landscape
Painreformu00a0Ltd would face intense competition, dependent on generic versus branded drugs. Innovation of novel non-opioid therapeutics, strong distribution networks, and favorable pricing contracts are key.
Major Acquisitions
Pain Solutions Inc.
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded portfolio of OTC pain relief products and market reach.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical: Moderate growth driven by demand for pain management products.
Future Projections: Hypothetical: Analysts project continued moderate growth in revenue and earnings.
Recent Initiatives: Hypothetical: Investment in R&D for non-opioid pain treatments; expansion into new markets.
Summary
Painreform Ltd, as a hypothetical company, needs to navigate a complex pain management market. Its success depends on diversification beyond opioids, managing regulatory pressures, and competing effectively with larger pharmaceutical companies. Strengths lie in a diversified portfolio, while weaknesses stem from opioid reliance. Growth can be boosted by novel products and market expansion; threats include regulatory changes and generic competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data and general market information.
Disclaimers:
The information provided is based on hypothetical data and general industry knowledge. It is not intended as financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Painreform Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-01 | Interim CEO & Executive Chairman Dr. Ehud Geller Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2 | Website https://www.painreform.com |
Full time employees 2 | Website https://www.painreform.com | ||
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.